» Articles » PMID: 35956937

Anticancer Effect of Cathelicidin LL-37, Protegrin PG-1, Nerve Growth Factor NGF, and Temozolomide: Impact on the Mitochondrial Metabolism, Clonogenic Potential, and Migration of Human U251 Glioma Cells

Abstract

Glioblastoma (GBM) is one of the most aggressive and lethal malignancy of the central nervous system. Temozolomide is the standard of care for gliomas, frequently results in resistance to drug and tumor recurrence. Therefore, further research is required for the development of effective drugs in order to guarantee specific treatments to succeed. The aim of current study was to investigate the effects of nerve growth factor (NGF), human cathelicidin (LL-37), protegrin-1 (PG-1), and temozolomide on bioenergetic function of mitochondria, clonogenicity, and migration of human U251 glioma cells. Colony formation assay was used to test the ability of the glioma cells to form colonies in vitro. The U251 glioma cells migration was evaluated using wound-healing assay. To study the mitochondrial metabolism in glioma cells we measured oxygen consumption rates (OCR) and extracellular acidification rates (ECAR) using a Seahorse XF cell Mito stress test kit and Seahorse XF cell Glycolysis stress kit, respectively. We revealed that LL-37, NGF, and TMZ show strong anti-tumorigenic activity on GMB. LL-37 (4 μM), TMZ (155 μM), and NGF (7.55 × 10 μM) inhibited 43.9%-60.3%, 73.5%-81.3%, 66.2% the clonogenicity of glioma U251 cells for 1-2 days, respectively. LL-37 (4 μM), and NGF (7.55 × 10 μM) inhibited the migration of U251 glioma cells on the third and fourth days. TMZ also inhibited the migration of human glioma U251 cells over 1-3 days. In contrast, PG-1 (16 μM) stimulated the migration of U251 glioma cells on the second, fourth, and sixth days. Anti-mitogenic and anti-migration activities of NGF, LL-37, and TMZ maybe are relation to their capacity to reduce the basal OCR, ATP-synthetase, and maximal respiration of mitochondria in human glioma U251 cells. Glycolysis, glycolytic capacity and glycolytic spare in glioma U251 cells haven`t been changed under the effect of NGF, LL-37, PG-1, and TMZ in regard to control level. Thus, LL-37 and NGF inhibit migration and clonogenicity of U251 glioma cells, which may indicate that these compounds have anti-mitogenic and anti-migration effects on human glioma cells. The study of the mechanisms of these effects may contribute in the future to the use of NGF and LL-37 as therapeutic agents for gliomas.

Citing Articles

From defense to offense: antimicrobial peptides as promising therapeutics for cancer.

Zare-Zardini H, Saberian E, Ghanipour-Meybodi R, Jenca A, Petrasova A, Jencova J Front Oncol. 2024; 14:1463088.

PMID: 39445062 PMC: 11496142. DOI: 10.3389/fonc.2024.1463088.


Anticancer peptides as novel immunomodulatory therapeutic candidates for cancer treatment.

Sood A, Jothiswaran V, Singh A, Sharma A Explor Target Antitumor Ther. 2024; 5(5):1074-1099.

PMID: 39351437 PMC: 11438574. DOI: 10.37349/etat.2024.00264.


Glioblastoma Multiforme: Sensitivity to Antimicrobial Peptides LL-37 and PG-1, and Their Combination with Chemotherapy for Predicting the Overall Survival of Patients.

Chernov A, Skliar S, Kim A, Tsapieva A, Pyurveev S, Filatenkova T Pharmaceutics. 2024; 16(9).

PMID: 39339270 PMC: 11435188. DOI: 10.3390/pharmaceutics16091234.


Paracrine function amplifies pro-tumor electrochemical signal within neuron-glioma synapses.

Hu Y, Hu P, Peng X Sci China Life Sci. 2024; 67(6):1318-1320.

PMID: 38619756 DOI: 10.1007/s11427-023-2544-0.


Expression of molecular markers and synergistic anticancer effects of chemotherapy with antimicrobial peptides on glioblastoma cells.

Chernov A, Kim A, Skliar S, Fedorov E, Tsapieva A, Filatenkova T Cancer Chemother Pharmacol. 2024; 93(5):455-469.

PMID: 38280033 DOI: 10.1007/s00280-023-04622-8.


References
1.
DAlterio C, Scala S, Sozzi G, Roz L, Bertolini G . Paradoxical effects of chemotherapy on tumor relapse and metastasis promotion. Semin Cancer Biol. 2019; 60:351-361. DOI: 10.1016/j.semcancer.2019.08.019. View

2.
Olivier C, Oliver L, Lalier L, Vallette F . Drug Resistance in Glioblastoma: The Two Faces of Oxidative Stress. Front Mol Biosci. 2021; 7:620677. PMC: 7873048. DOI: 10.3389/fmolb.2020.620677. View

3.
Chen X, Zou X, Qi G, Tang Y, Guo Y, Si J . Roles and Mechanisms of Human Cathelicidin LL-37 in Cancer. Cell Physiol Biochem. 2018; 47(3):1060-1073. DOI: 10.1159/000490183. View

4.
Bazzoni R, Bentivegna A . Role of Notch Signaling Pathway in Glioblastoma Pathogenesis. Cancers (Basel). 2019; 11(3). PMC: 6468848. DOI: 10.3390/cancers11030292. View

5.
Wnorowska U, Fiedoruk K, Piktel E, Prasad S, Sulik M, Janion M . Nanoantibiotics containing membrane-active human cathelicidin LL-37 or synthetic ceragenins attached to the surface of magnetic nanoparticles as novel and innovative therapeutic tools: current status and potential future applications. J Nanobiotechnology. 2020; 18(1):3. PMC: 6939332. DOI: 10.1186/s12951-019-0566-z. View